Ren Xiaoxiang, Xu Ruixue, Xu Chenjie, Su Jiacan
Organoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai, China.
National Center for Translational Medicine (Shanghai) SHU Branch, Shanghai University, Shanghai, China.
Biomater Transl. 2024 Mar 28;5(1):46-58. doi: 10.12336/biomatertransl.2024.01.005. eCollection 2024.
Exosomes, nanoscopic extracellular vesicles produced by cells, are pivotal in mediating intracellular communication by transporting nucleic acids, proteins, lipids, and other bioactive molecules, thereby influencing physiological and pathological states. Their endogenous origin and inherent diversity confer distinct advantages over synthetic vehicles like liposomes and nanoparticles in diagnostic and therapeutic applications. Despite their potential, the clinical utility of exosomes is hampered by challenges such as limited storage stability, yield, purity, and targeting efficiency. This review focuses on exosomes as targeted therapeutic agents, examining their biogenesis, classification, isolation, and characterisation, while also addressing the current limitations in yield, purity, and targeting. We delve into the literature to propose optimisation strategies that can enhance their therapeutic efficacy and accelerate the translation of exosome-based therapies into clinical practice.
外泌体是细胞产生的纳米级细胞外囊泡,通过运输核酸、蛋白质、脂质和其他生物活性分子在介导细胞内通讯中起关键作用,从而影响生理和病理状态。它们的内源性起源和固有多样性在诊断和治疗应用中比脂质体和纳米颗粒等合成载体具有明显优势。尽管外泌体具有潜力,但其临床应用受到诸如储存稳定性有限、产量、纯度和靶向效率等挑战的阻碍。本综述重点关注外泌体作为靶向治疗剂,研究其生物发生、分类、分离和表征,同时也探讨目前在产量、纯度和靶向方面的局限性。我们深入研究文献以提出优化策略,可提高其治疗效果并加速基于外泌体的疗法转化为临床实践。